MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT.

OBJECTIVE To determine an optimal MR imaging technique and pulse sequence for evaluating mural and serosal disease of the gastrointestinal tract, we administered 2% oral barium sulfate and obtained fat-suppressed gadolinium-enhanced breath-hold fast multiplanar spoiled gradient-recalled (FMPSPGR) MR images. We then compared these images with spin-echo T1-weighted and T2-weighted fast spin-echo MR images and with CT images. SUBJECTS AND METHODS Thirty-one patients with suspected diseases of the gastrointestinal tract were imaged with spin-echo T1-weighted, fast spin-echo T2-weighted, and fat-saturated gadolinium-enhanced FMPSPGR MR imaging. Before undergoing MR imaging, all patients received 1350 ml of 2% barium sulfate oral contrast media. For CT scans, patients received 120 ml of iodinated i.v. contrast material and 2% barium sulfate oral contrast material. CT and MR images were retrospectively and independently reviewed by two radiologists for ability to see normal bowel wall, for the presence of abnormal gastrointestinal tract mural thickening or enhancement, and for overall gastrointestinal tract visualization. Findings were correlated with surgical findings, endoscopy, and barium studies. RESULTS Ten patients had benign disease, 16 had malignant gastrointestinal tract disease, and five had no gastrointestinal tract abnormalities. In 94% of patients, the gadolinium- and barium-enhanced FMPSPGR MR images were superior to CT and spin-echo MR sequences for depicting the wall of the normal bowel (p < .001). For the two observers, the FMPSPGR MR images with i.v. and oral contrast material were seen as revealing 94% and 95% of bowel segments with malignant or inflammatory mural thickening or serosal tumor. In comparison, CT revealed 64% and 72% (p < .01 and p < .0001, respectively), fast spin-echo T2-weighted MR images revealed 21% and 28% (p < .0001), and T1-weighted MR images revealed 17% and 18% (p < .0001). The gadolinium- and barium-enhanced MR images were preferred for overall gastrointestinal tract visualization in 65% of patients compared with 1% for CT scans (p < .001). In 32% of patients, the enhanced MR images were equivalent to CT images. CONCLUSION MR evaluation of the gastrointestinal tract requires bowel distention with oral contrast material as well as motion reduction techniques, including glucagon and rapid gradient-echo pulses that allow breath-hold imaging. Fat-suppressed gadolinium-enhanced FMPSPGR MR imaging with diluted barium oral contrast media is effective for imaging benign and malignant mural and serosal abnormalities of the gastrointestinal tract.

[1]  G. Rollandi,et al.  [Magnetic resonance imaging of the small intestine and colon in Crohn's disease]. , 1996, La Radiologia medica.

[2]  The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers. , 1991, AJR. American journal of roentgenology.

[3]  T. Winter,et al.  Upper gastrointestinal tract and abdomen: water as an orally administered contrast agent for helical CT. , 1996, Radiology.

[4]  J. Heiken,et al.  Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon. , 1991, Radiology.

[5]  R Weissleder,et al.  First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. , 1990, Radiology.

[6]  C. Claussen,et al.  Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy. , 1991, Radiology.

[7]  G. Krestin,et al.  Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. , 1995, Endoscopy.

[8]  J. Fitzsimmons,et al.  Barium sulfate suspension as a negative oral MRI contrast agent: in vitro and human optimization studies. , 1991, Magnetic resonance imaging.

[9]  R. Semelka,et al.  MR imaging of the gastrointestinal tract. , 1995, Magnetic resonance imaging clinics of North America.

[10]  F. Joosten,et al.  Staging of Rectal Carcinoma Using MR Double Surface Coil, MR Endorectal Coil, and Intrarectal Ultrasound: Correlation with Histopathologic Findings , 1995, Journal of computer assisted tomography.

[11]  S. Mirowitz Contrast enhancement of the gastrointestinal tract on MR images using intravenous gadolinium-DTPA , 1993, Abdominal Radiology.

[12]  T. Pilgram,et al.  MR imaging of crohn disease: Use of perflubron as a gastrointestinal contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[13]  B. Marincek,et al.  Oral superparamagnetic contrast agent (ferumoxsil): Tolerance and efficacy in MR imaging of gynecologic diseases , 1995, Journal of magnetic resonance imaging : JMRI.

[14]  D. Mitchell,et al.  Comparison of Kaopectate with barium for negative and positive enteric contrast at MR imaging. , 1991, Radiology.

[15]  R. Low,et al.  Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. , 1995, Radiology.

[16]  G. Ghahremani,et al.  CT features of ulcerative colitis and Crohn's disease. , 1996, AJR. American journal of roentgenology.

[17]  D. Rubin,et al.  Liquid oral magnetic particles as a gastrointestinal contrast agent for MR imaging: Efficacy in vivo , 1993, Journal of magnetic resonance imaging : JMRI.

[18]  T. Kim,et al.  Extraserosal invasion in advanced gastric cancer: evaluation with MR imaging. , 1994, Radiology.

[19]  R. Semelka,et al.  Small bowel neoplastic disease: Demonstration by MRI , 1996, Journal of magnetic resonance imaging : JMRI.

[20]  B. McNeil,et al.  CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. , 1996, Radiology.

[21]  P R Mueller,et al.  An aqueous gastrointestinal contrast agent for use in echo‐planar MR imaging , 1992, Magnetic resonance in medicine.

[22]  G. Glazer,et al.  Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials. , 1993, Radiology.

[23]  F. Kelvin,et al.  Obstruction ofthe Small Intestine: Accuracy and Role ofCT In Diagnosis' , 1993 .

[24]  R. Semelka,et al.  Comparison of magnetic resonance imaging and endoscopy in distinguishing the type and severity of inflammatory bowel disease. , 1994, Journal of clinical gastroenterology.

[25]  T. Jaw,et al.  MRI Manifestations of gastrointestinal wall thickening , 1994, Abdominal Imaging.

[26]  R. Semelka,et al.  Bowel disease: Prospective comparison of CT and 1.5‐T pre‐ and postcontrast MR imaging with T1‐weighted fat‐suppressed and breath‐hold FLASH sequences , 1991, Journal of magnetic resonance imaging : JMRI.

[27]  R. Semelka,et al.  Crohn's disease. Pilot study comparing MRI of the abdomen with clinical evaluation. , 1995, Journal of clinical gastroenterology.